Ron MBA - Nuvectis Pharma Chairman, CoFounder
| NVCT Stock | USD 6.76 0.02 0.30% |
Insider
Ron MBA is Chairman, CoFounder of Nuvectis Pharma
| Age | 59 |
| Address | 1 Bridge Plaza, Fort Lee, NJ, United States, 07024 |
| Phone | 201 614 3150 |
| Web | https://www.nuvectis.com |
Nuvectis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.6086) % which means that it has lost $0.6086 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4) %, meaning that it created substantial loss on money invested by shareholders. Nuvectis Pharma's management efficiency ratios could be used to measure how well Nuvectis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.1 in 2025. Return On Capital Employed is likely to drop to -1.77 in 2025. Change To Liabilities is likely to gain to about 5 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 4.3 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| George Eldridge | Aerovate Therapeutics | 62 | |
| Lauren White | C4 Therapeutics | N/A | |
| MD MSc | Centessa Pharmaceuticals PLC | 64 | |
| Lance Laing | Celcuity LLC | 63 | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Timothy CPA | Werewolf Therapeutics | 67 | |
| Courtney Dugan | Olema Pharmaceuticals | N/A | |
| Behrad Derakhshan | Edgewise Therapeutics | 45 | |
| Alfredo Castro | Ikena Oncology | N/A | |
| Cynthia SeidelDugan | Werewolf Therapeutics | 65 | |
| Lina Gugucheva | NewAmsterdam Pharma | 37 | |
| Tanya MS | Replimune Group | 53 | |
| David Myles | Olema Pharmaceuticals | 62 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Timothy Pigot | Aerovate Therapeutics | 53 | |
| Joshua Kazam | Kronos Bio | 48 | |
| John Moriarty | Olema Pharmaceuticals | 56 | |
| Randi MD | Werewolf Therapeutics | 69 | |
| MBA MD | Centessa Pharmaceuticals PLC | 51 | |
| PharmD Faltaos | Olema Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.4 | ||||
| Return On Asset | -0.61 |
Nuvectis Pharma Leadership Team
Elected by the shareholders, the Nuvectis Pharma's board of directors comprises two types of representatives: Nuvectis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nuvectis. The board's role is to monitor Nuvectis Pharma's management team and ensure that shareholders' interests are well served. Nuvectis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nuvectis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shay Shemesh, Executive CoFounder | ||
| Michael CPA, Vice Finance | ||
| Ron MBA, Chairman, CoFounder | ||
| Enrique Poradosu, Executive CoFounder |
Nuvectis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nuvectis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.4 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | 113.44 M | ||||
| Shares Outstanding | 19.32 M | ||||
| Shares Owned By Insiders | 54.91 % | ||||
| Shares Owned By Institutions | 7.70 % | ||||
| Number Of Shares Shorted | 1.48 M | ||||
| Price To Book | 11.88 X | ||||
| EBITDA | (22.9 M) | ||||
| Net Income | (22.26 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.